Close Menu

NEW YORK (GenomeWeb News) – Following Thermo Fisher Scientific's announcement today that it is buying One Lambda for $925 million, ratings agency Moody's Investors Service downgraded the company's senior unsecured rating and all rated senior unsecured notes.

Thermo Fisher's unsecured senior rating and notes were downgraded one notch to Baa1 from A3. Moody's affirmed the Prime-2 rating on Thermo Fisher's commercial paper program and said that the rating outlook is stable.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A New Zealand minister says the country's genetic modification laws need to be re-examined to help combat climate change, the New Zealand Herald reports.

A new analysis finds some cancers receive more nonprofit dollars than others.

An Australian mother's conviction in the deaths of her children may be re-examined after finding that two of the children carried a cardiac arrhythmia-linked gene variant.

In Science this week: comparative analysis of sex differences in mammal gene expression, and more.